Cargando…

CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion

BACKGROUND: Ovarian carcinoma (OvCa) is the most lethal gynecological malignancy among women and its poor prognosis is mainly due to metastasis. Chemokine receptor CCR9 is primarily expressed by a small subset of immune cells and its only natural ligand, CCL25, is largely expressed in the thymus, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Erica L, Singh, Rajesh, Singh, Shailesh, Johnson-Holiday, Crystal M, Grizzle, William E, Partridge, Edward E, Lillard, James W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927595/
https://www.ncbi.nlm.nih.gov/pubmed/20649989
http://dx.doi.org/10.1186/1477-7819-8-62
_version_ 1782185772964642816
author Johnson, Erica L
Singh, Rajesh
Singh, Shailesh
Johnson-Holiday, Crystal M
Grizzle, William E
Partridge, Edward E
Lillard, James W
author_facet Johnson, Erica L
Singh, Rajesh
Singh, Shailesh
Johnson-Holiday, Crystal M
Grizzle, William E
Partridge, Edward E
Lillard, James W
author_sort Johnson, Erica L
collection PubMed
description BACKGROUND: Ovarian carcinoma (OvCa) is the most lethal gynecological malignancy among women and its poor prognosis is mainly due to metastasis. Chemokine receptor CCR9 is primarily expressed by a small subset of immune cells and its only natural ligand, CCL25, is largely expressed in the thymus, which involutes with age. Other than the thymus, CCL25 is expressed by the small bowel. Interactions between CCL25 and CCR9 have been implicated in leukocyte trafficking to the small bowel, a frequent metastatic site for OvCa cells. The current study shows OvCa tissue and cells significantly express CCR9, which interacts with CCL25 to support carcinoma cell migration and invasion. METHODS: RT-PCR and flow cytometry techniques were used to quantify the expression CCR9 by OvCa cells. OvCa tissue microarrays (TMA) was used to confirm CCR9 expression in clinical samples. The Aperio ScanScope scanning system was used to quantify immunohistochemical staining. Cell invasion and migration assays were performed using cell migration and matrigel invasion chambers. Matrix metalloproteinase (MMP) mRNAs were quantified by RT-PCR and active MMPs were quantified by ELISA. RESULTS: Our results show significantly (p < 0.001) higher expression of CCR9 by mucinous adenocarcinoma, papillary serous carcinoma, and endometriod ovarian carcinoma cases, than compared to non-neoplastic ovarian tissue. Furthermore, CCR9 expression was significantly elevated in OvCa cell lines (OVCAR-3 and CAOV-3) in comparison to normal adult ovarian epithelial cell mRNA. OvCa cells showed higher migratory and invasive potential towards chemotactic gradients of CCL25, which was inhibited by anti-CCR9 antibodies. Expression of collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), and stromelysins (MMP-3, -10, and -11) by OvCa cells were modulated by CCL25 in a CCR9-dependent fashion. CONCLUSIONS: These results demonstrate both biological significance and clinical relevance of CCL25 and CCR9 interactions in OvCa cell metastasis.
format Text
id pubmed-2927595
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29275952010-08-25 CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion Johnson, Erica L Singh, Rajesh Singh, Shailesh Johnson-Holiday, Crystal M Grizzle, William E Partridge, Edward E Lillard, James W World J Surg Oncol Research BACKGROUND: Ovarian carcinoma (OvCa) is the most lethal gynecological malignancy among women and its poor prognosis is mainly due to metastasis. Chemokine receptor CCR9 is primarily expressed by a small subset of immune cells and its only natural ligand, CCL25, is largely expressed in the thymus, which involutes with age. Other than the thymus, CCL25 is expressed by the small bowel. Interactions between CCL25 and CCR9 have been implicated in leukocyte trafficking to the small bowel, a frequent metastatic site for OvCa cells. The current study shows OvCa tissue and cells significantly express CCR9, which interacts with CCL25 to support carcinoma cell migration and invasion. METHODS: RT-PCR and flow cytometry techniques were used to quantify the expression CCR9 by OvCa cells. OvCa tissue microarrays (TMA) was used to confirm CCR9 expression in clinical samples. The Aperio ScanScope scanning system was used to quantify immunohistochemical staining. Cell invasion and migration assays were performed using cell migration and matrigel invasion chambers. Matrix metalloproteinase (MMP) mRNAs were quantified by RT-PCR and active MMPs were quantified by ELISA. RESULTS: Our results show significantly (p < 0.001) higher expression of CCR9 by mucinous adenocarcinoma, papillary serous carcinoma, and endometriod ovarian carcinoma cases, than compared to non-neoplastic ovarian tissue. Furthermore, CCR9 expression was significantly elevated in OvCa cell lines (OVCAR-3 and CAOV-3) in comparison to normal adult ovarian epithelial cell mRNA. OvCa cells showed higher migratory and invasive potential towards chemotactic gradients of CCL25, which was inhibited by anti-CCR9 antibodies. Expression of collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), and stromelysins (MMP-3, -10, and -11) by OvCa cells were modulated by CCL25 in a CCR9-dependent fashion. CONCLUSIONS: These results demonstrate both biological significance and clinical relevance of CCL25 and CCR9 interactions in OvCa cell metastasis. BioMed Central 2010-07-22 /pmc/articles/PMC2927595/ /pubmed/20649989 http://dx.doi.org/10.1186/1477-7819-8-62 Text en Copyright ©2010 Johnson et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Johnson, Erica L
Singh, Rajesh
Singh, Shailesh
Johnson-Holiday, Crystal M
Grizzle, William E
Partridge, Edward E
Lillard, James W
CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title_full CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title_fullStr CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title_full_unstemmed CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title_short CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
title_sort ccl25-ccr9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927595/
https://www.ncbi.nlm.nih.gov/pubmed/20649989
http://dx.doi.org/10.1186/1477-7819-8-62
work_keys_str_mv AT johnsonerical ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT singhrajesh ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT singhshailesh ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT johnsonholidaycrystalm ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT grizzlewilliame ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT partridgeedwarde ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion
AT lillardjamesw ccl25ccr9interactionmodulatesovariancancercellmigrationmetalloproteinaseexpressionandinvasion